A month ago we’ve reported that Enzysurge out of Rosh Ha’ayin, Israel was working toward getting FDA approval for its SilverStream wound therapy system. And in no time the company is already announcing regulatory clearance to sell both its prescription and over-the-counter systems in the US.
Here are some details about the DermaStream technology:
The patent pending DermaStream CST device provides the mechanism for EnzySurge’s proprietary Continuous Streaming Therapy™ (CST). CST is a modality based on continuously streaming of fresh therapeutic solutions to the wound bed while removing exudates by vacuum assisted drainage throughout the treatment cycle. The combination of the DermaStream CSTdesign and the CST action produces negative pressure above the wound without the need for external equipment.
DermaStream is designed to ensure ongoing, uniform flow of fresh solutions over the entire wound bed The use of therapeutic solutions allows for a broad wound management platform DermaStreamCST vacuum assisted drainage continuously removes exudate and infectious material from the wound environment. Gravity-induced negative pressure removes exudates including removal of loose necrotic burden DermaStream CST is a disposable, single patient use device. It is designed to provide negative pressure above the wound bed without expensive external equipment.
Press release: EnzySurge Receives FDA Approval for SilverStream™ Innovative Wound Management Solution…
Product page: DermaStream…
Flashbacks: DermaStream CST for Active Wound Management; DermaStream Chronic Wound Treatment Technology